Cargando…
AMCP Partnership Forum: Driving New Advances in Dyslipidemia Management
SUMMARY: Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors are specialty medications approved for the treatment of dyslipidemia. Because dyslipidemia is a prevalent and chronic condition, the costs associated with PCSK9 inhibitors must be carefully weighed against the benefits that they pr...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398088/ https://www.ncbi.nlm.nih.gov/pubmed/27023696 http://dx.doi.org/10.18553/jmcp.2016.22.4.426 |